The Aduhelm Files
This investigative series explores the science, money and politics behind the approval of the Alzheimer’s drug aducanumab. Read to learn more about this controversial drug and its implications for the future of Alzheimer’s treatment.
All Coverage
STAT Plus: FDA, Biogen, and an Alzheimer’s drug approval: 8 key takeaways from congressional investigation
STAT Plus: ‘Rife with irregularities’: Congressional investigation reveals FDA’s approval of Aduhelm marked by secret discussions, breaches of protocol
